Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Dose Dense Sequential Chemotherapy in Neoadjuvant HER2- Breast Cancer
NCT01985841Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Oct 2011
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Hellenic Oncology Research Group. Started Oct 2011; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01985841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01985841.